Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 11, 2019 03:21 ET | Source: ASLAN PHARMACEUTICALS LIMITED

ASLAN Pharmaceuticals Announces Topline Results From TreeTopp Global Pivotal Study of Varlitinib in Biliary Tract Cancer

- The study did not meet its co-primary endpoints. The primary analysis of PFS yielded a hazard ratio of 0.90 in favour of varlitinib, and the ORR for varlitinib was 9.4% versus 4.8% in the control...
October 31, 2019 03:37 ET | Source: ASLAN PHARMACEUTICALS LIMITED

ASLAN Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Corporate Update

SINGAPORE, Oct. 31, 2019 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497), a clinical-stage oncology and immunology focused biopharma company, today reported financial results for...
October 18, 2019 03:35 ET | Source: ASLAN PHARMACEUTICALS LIMITED

ASLAN Pharmaceuticals Announces Closing of US$3 Million Loan Facility

SINGAPORE, Oct. 18, 2019 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497), a clinical-stage oncology and immunology focused biopharma company, today announced it has secured a US$3...
October 02, 2019 02:30 ET | Source: ASLAN PHARMACEUTICALS LIMITED

New Data Presented on ASLAN’s varlitinib at ESMO 2019

SINGAPORE, Oct. 02, 2019 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497), a clinical-stage oncology and immunology focused biopharma company, today announced the presentation of...
September 19, 2019 03:50 ET | Source: ASLAN PHARMACEUTICALS LIMITED

ASLAN Pharmaceuticals Presents Late-Breaking Data From Phase 2 Study in China Testing Varlitinib in Second Line Biliary Tract Cancer at CSCO

- Biliary tract cancer (BTC) patients treated with varlitinib plus capecitabine in second line achieved a response rate of 11% including two complete responses, median PFS of 2.7 months and OS of 5.8...
September 10, 2019 05:14 ET | Source: ASLAN Pharmaceuticals Limited

Abstract on ASLAN Pharmaceuticals’ Varlitinib Accepted for Poster Presentation at ESMO Asia Congress 2019

SINGAPORE, Sept. 10, 2019 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497), a clinical-stage oncology and immunology focused biopharma company, today announced that an abstract on...
August 27, 2019 06:00 ET | Source: ASLAN Pharmaceuticals Limited

New Data From Aslan’s Study of Varlitinib in China Accepted as Late-Breaking Oral Presentation at 2019 CSCO Annual Meeting

SINGAPORE, Aug. 27, 2019 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497), a clinical-stage oncology and immunology focused biopharma company, today announced that a late-breaking...
August 13, 2019 04:03 ET | Source: ASLAN Pharmaceuticals Limited

ASLAN Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Corporate Update

SINGAPORE, Aug. 13, 2019 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497), a clinical-stage oncology and immunology focused biopharma company, today reported financial results for...
May 10, 2019 04:15 ET | Source: ASLAN Pharmaceuticals Limited

ASLAN Pharmaceuticals’ Varlitinib Selected by Leading Korean Gastric Cancer Group for Study in Second-Line Gastric Cancer

- K-MASTER, Korea’s leading precision medicine research group, to conduct phase 1b/2 umbrella study testing varlitinib as a second-line treatment in HER1/HER2 co-expressing advanced or metastatic...
February 26, 2019 17:35 ET | Source: ASLAN Pharmaceuticals Limited

ASLAN Pharmaceuticals to Partner With BioGenetics on Commercialisation of Varlitinib in South Korea

SINGAPORE, Feb. 27, 2019 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497), a clinical-stage oncology-focused biopharmaceutical company developing novel therapeutics for global...

Next Page keyboard_arrow_right